Lantern Pharma Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Loss of $4.33 Million, EPS at $0.40, Down from $4.96 Million Loss and $0.46 EPS in Q2 2024
Lantern Pharma Inc. reported its financial results for the second quarter of 2025, highlighting a net loss of $4.33 million for the quarter, compared to a net loss of $4.96 million in the same period in 2024. This represents a slight improvement in net loss year-over-year. Research and development expenses for the quarter decreased to $3.1 million from $3.9 million the previous year, reflecting disciplined cost management while advancing clinical programs. General and administrative expenses were stable at approximately $1.6 million compared to $1.5 million in the same quarter of 2024. The company also achieved a major milestone by successfully completing enrollment for the LP-184 Phase 1a clinical trial, with 65 patients enrolled across various solid tumors, including glioblastoma. The maximum tolerated dose and recommended Phase 2 dose for LP-184 were established, which will enable advancement to upcoming Phase 1b/2 trials planned for recurrent triple-negative breast cancer and recurrent bladder cancer. Additionally, a remarkable complete response was observed in a patient from the HARMONIC™ trial with advanced non-small cell lung cancer. Lantern Pharma's anticipated expenditures are expected to fund operating expenses and capital expenditure requirements at least into June 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023489), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.